EAElham Aflaki

Elham Aflaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elham Aflaki has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Investigation of clinical characteristics of COVID-19 infection in rheumatoid patients on immunosuppressive drugs: a retrospective case–control study

    by Faezeh Sehatpour, Elham Aflaki

    Backgrounds: Cytokine storm has been considered a major pathogenic in severe COVID-19 patients with severe disease. Inflammatory cytokines, such as interleukin-6(IL-6), IL-1, and tumor necrosis factor alpha (TNF-α) released from the lung epithelium during COVID-19 infection resemble those involved in inflammatory rheumatic diseases. Immunosuppressive drugs are central in managing any rheumatologic diseases. Immunosuppressive drugs are central in managing any rheumatologic diseases, and prolonged use may alter clinical features of COVID-19 in these patients. Objective: To determine the clinical findings and disease severity of COVID-19 infection in patients with rheumatic diseases under immunosuppressive therapy. Method: A retrospective case–control study of 981 patients with rheumatic diseases attending university—affiliated clinics and hospital in Shiraz, Iran, including 539 patients with confirmed COVID-19 infection and 442 COVID-19—negative controls without documented infection. Results: Pre-exposure to prednisolone was associated with increased severity of COVID-19 (adjusted OR 2.52; 95% CI 1.19–4.26). Methotrexate (MTX) use was associated with milder disease (OR 0.35; 95% CI 0.21–0.58). Among biologic therapies, anti-TNF agents (etanercept, infliximab) users showed a significant association with lower severity (OR 0.33; 95% CI 0.16–0.69), whereas the smaller rituximab (anti-CD20) subgroup (n = 54) was insufficiently powered for separate analysis. Other conventional DMARDs showed no significant effect. Hydroxychloroquine did not show protective effects. Conclusion: In this cohort of Iranian patients with rheumatic diseases, prior corticosteroid use was associated with increased COVID-19 incidence and severity, whereas MTX and anti-TNF biologics were associated with milder disease outcomes. Due to sample size limitations and contrasting literature on rituximab (anti-CD20), we caution against generalizing protective effects across all biologics. Our findings suggest that immunosuppressive therapy influences COVID-19 outcomes, but prospective studies are needed to elucidate mechanisms and causality.

  • Open Access

    Indications, response, and side effects of biologic treatment in Behçet’s disease: an 8-year study with follow-up

    by Saeedeh Shenavandeh, Elham Aflaki, Maryam Rasti RastiJahromi, Afshin Borhani Haghighi, Mohammad Ali Nazarinia

    Introduction: The treatment of Behçet’s disease has improved significantly with the introduction of biologic therapies. However, there is still a need for more information about their use. This study aimed to evaluate the indications, response, and side effects of biologic agents in patients...

  • Open Access

    Mortality and Years of Life Lost (YLL) Trends in Musculoskeletal Disorders in the South of Iran, 2004-2019

    by Habibollah Azarbakhsh, Elham Aflaki, Jafar Hassanzadeh, Elahe Piraee, Ata Miyar, Alireza Mirahmadizadeh


  • Successful treatment of classic pyoderma gangrenosum with intralesional infliximab injection: A case report

    by Kourosh Ahmadi, Elham Aflaki, Mojgan Akbarzade Jahromi, Ladan Dastgheib

    Pyoderma gangrenosum (PG) is a rare dermatological disease characterized by the rapid development of painful skin ulcers. While systemic infliximab is considered a standard treatment for patients with PG, herein, we report our success with the use of intralesional infliximab in a 40-year-old woman with systemic lupus erythematosus (SLE) and PG.


  • Open Access

    Cost‐Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept

    by Ahmad Gholami, Jassem Azizpoor, Elham Aflaki, Mehdi Rezaee, Khosro Keshavarz

    Introduction. Rheumatoid arthritis (RA) is a chronic progressive inflammatory disease that causes joint destruction. The condition imposes a significant economic burden on patients and societies. The present study is aimed at evaluating the cost‐effectiveness of Infliximab, Adalimumab, and Etanercept in treating rheumatoid arthritis in Iran. Methods. This is a cost‐effectiveness study of economic evaluation in which the Markov model was used. The study was carried out on 154 patients with rheumatoid arthritis in Fars province taking Infliximab, Adalimumab, and Etanercept. The patients were selected through sampling. In this study, the cost data were collected from a community perspective, and the outcomes were the mean reductions in DAS‐28 and QALY. The cost data collection form and the EQ‐5D questionnaire were also used to collect the required data. The results were presented in the form of an incremental cost‐effectiveness ratio, and the sensitivity analysis was used to measure the robustness of the study results. The TreeAge Pro and Excel softwares were used to analyze the collected data. Results. The results showed that the mean costs and the QALY rates in the Infliximab, Adalimumab, and Etanercept arms were $ 79,518.33 and 12.34, $ 91,695.59 and 13.25, and $ 87,440.92 and 11.79, respectively. The one‐way sensitivity analysis confirmed the robustness of the results. In addition, the results of the probabilistic sensitivity analysis (PSA) indicated that on the cost‐effectiveness acceptability curve, Infliximab was in the acceptance area and below the threshold in 77% of simulations. The scatter plot was in the mentioned area in 81% and 91% of simulations compared with Adalimumab and Etanercept, respectively, implying lower costs and higher effectiveness than the other two alternatives. Therefore, the strategy was more cost‐effective. Conclusion. According to the results of this study, Infliximab was more cost‐effective than the other two medications. Therefore, it is recommended that physicians use this medication as the priority in treating rheumatoid arthritis. It is also suggested that health policymakers consider the present study results in preparing treatment guidelines for RA.


  • Open Access

    Inflammatory and T Helper 17/ Regulatory T Cells Related Cytokines Balance in Cutaneous Lupus Erythematosus (CLE)

    by Mohammad-Reza Yazdani, Elham Aflaki, Nasser Gholijani

    The cutaneous lupus erythematosus (CLE) is a common manifestation among systemic lupus erythematosus (SLE) patients. Malar rash and discoid lupus (DLE) are in the category of acute and chronic CLE, respectively. The pathogenesis of CLE is multifactorial, and cytokine imbalances contribute to immune dysfunction and the induction of organ damage. Many aspects of cytokine dysregulation are still unclear in SLE and in particular CLE. Therefore, we concurrently measured the inflammatory [Tumor necrosis factor-alpha (TNF-α) and Interleukin (IL)-6)], T helper (Th)-17 (IL-17 and IL-23) and regulatory T cells [Transforming growth factor-beta (TGFβ) and IL-10)]-related cytokines in patients with CLE (patients with malar rash and/or DLE) and compared them with SLE patients and healthy individuals (n=25 in each group, a total of 75 patients). The serum levels of cytokines were assessed by Enzyme-Linked Immunosorbent Assay (ELISA) method. IL-6 cytokine was significantly higher in SLE, DLE, and malar rash patients compared to those in healthy controls (p=0.025) and in patients with arthralgia (p=0.038), and gastrointestinal involvement (p=0.048). IL-17 was significantly higher in malar rash patients compared to normal individuals (p=0.023), SLE (p=0.008) and DLE patients (p=0.019) and in patients with oropharyngeal ulcer (p=0.05) but, IL-23 was significantly higher only in DLE patients than healthy controls (p=0.019). In conclusion, inflammatory cytokines such as IL-6 involved in inflammation and differentiation of Th17 cells are probably responsible in part for Th17 activity in CLE. IL-17, IL-23, and IL-6/IL-6R (IL-6 receptor) inhibitors may be good treatments for CLE patients. So targeting these cytokines activity pathways can improve the CLE treatment strategy and may open a novel guideline for SLE and CLE treatment.